Table 2.
Univariable and Multivariable Analysis for factors affecting Overall Survival and Local Progression
| Variable | Categorya | Overall Survival | Local Progression | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariable Analysis | Univariate analysis | Multivariable Analysis | ||||||
| HR (95% CI) | p-valueb | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Transplant post SBRT | Yes vs No | 0.08 (0.02–0.31) | 0.0003 | 0.06 (0.02–0.25) | <0.0001 | - | - | - | - |
| Pre-treatment CP score | A vs B,C | 0.50 (0.36–0.70) | <0.0001 | 0.42 (0.29–0.60) | <0.0001 | - | - | - | - |
| AFP | ≤10 (median)vs >10 | 0.67 (0.49–0.91) | 0.0112 | 0.61 (0.44–0.83) | 0.0020 | - | - | - | - |
| ECOG | 0 vs ≥1 | 0.66 (0.48–0.89) | 0.0070 | 0.71 (0.51–0.97) | 0.0339 | - | - | - | - |
| Cirrhosis | Yes vs No | 1.69 (1.03–2.80) | 0.0398 | 0.83 (0.40–1.74) | 0.6233 | - | - | ||
| Etiology of cirrhosis (ref=None) | HBV | 1.01 (0.53–1.93) | 0.0441 | NS | NS | 2.05 (0.93–4.48) | 0.1601 | - | - |
| HCV | 1.57 (0.93–2.63) | 1.00 (0.49–2.01) | - | - | |||||
| Non-viral | 1.80 (1.07–3.05) | 1.60 (0.69–3.71) | - | - | |||||
| Pre-treatment ALBI | Grade 1 vs Grade 2/3 | 0.75 (0.54–1.05) | 0.0897 | d | - | - | - | - | - |
| Age | >70 vs < 70 yrs. | 0.78 (0.58–1.06) | 0.1121 | - | - | - | - | - | - |
| T-stage | T1 vs T2/3a | 0.79 (0.57–1.09) | 0.1451 | - | - | 0.98 (0.57–1.67) | 0.9388 | - | - |
| Decline in CP score | ≥ 2 points vs <2 points | 1.79 (1.15–2.77) | 0.0093 | e | - | - | - | - | - |
| No of tumors | 1 (ref) 2–3 4 |
1.26 (0.91–1.75) 0.78 (0.25–2.46) |
0.3363 |
- | - | Ref | 0.7451 | - | - |
| 1.10 (0.63–1.91) | - | - | |||||||
| 0.67 (0.19–2.43) | - | - | |||||||
| Prior Liver directed therapy | Yes vs No | 1.06 (0.78–1.45) | 0.7152 | - | 2.08 (0.50–8.64) | 0.3147 | - | - | |
| Tumor size | ≤ 3 cm vs >3 cm | 0.96 (0.71–1.31) | 0.8143 | - | 0.53 (0.31–0.91) | 0.0212 | 0.53 (0.29–0.98 | 0.0423 | |
| ≤ 5 cm or >5 cm | 0.94 (0.64–1.40) | 0.7725 | - | 0.67 (0.33–1.36) | 0.2674 | - | - | ||
| Time since diagnosis of HCC | < 9 months vs>9 months | 0.98 (0.72–1.32) | 0.8669 | - | - | - | - | - | |
| Local progression | Yes vs No | 0.95 (0.63–1.42) | 0.7953 | - | - | - | - | - | |
| Fiducials | Yes vs No | - | - | - | 0.00 | <0.0001 | e | ||
| Respiratory motion management | Breath hold vs. compression/free breathing | - | - | - | 0.47 (0.26–0.84) | 0.0106 | 0.52 (0.28–0.98) | 0.0441 | |
| Total SBRT physical dose | - | - | f | 0.96 (0.93–0.99) | 0.0244 | - | - | ||
| Total GTV | - | - | - | 1 (0.999–1.001) | 0.4592 | - | - | ||
a
Reference category is the latter category in each variable.
b
Bold values indicate statistical significance.
c
As pre-treatment ALBI was correlated with pre-treatment CP score, hence ALBI was not included in the model
d
Was not included in the model as was correlated to Pre-treatment CP score
e
Not included in the model as there were too few events
f
Prescribed dose was not included in multivariable analysis for overall survival due to the inherent bias in dose allocation due to differing dose allocation strategies at both the participating institutions